Differences in kidney-specific DPP-4 inhibition by linagliptin and sitagliptin

Luippold G, Mark M, Klein T, Amann KU, Daniel C (2018)

Publication Type: Journal article

Publication year: 2018

Journal

Diabetes Research and Clinical Practice Elsevier

Book Volume: 143

Pages Range: 199-203

DOI: 10.1016/j.diabres.2018.07.009

Abstract

The two dipeptidyl peptidase (DPP)-4 inhibitors, linagliptin and sitagliptin, were shown to exert different binding kinetics in vitro. Twenty-four hours after oral dosing particularly in vivo inhibition of renal-specific DPP-4 activity was more sustained in Sprague Dawley rats after exposure to linagliptin than it was after sitagliptin.

Authors with CRIS profile

Kerstin Ute Amann Department of Nephropathology Christoph Daniel Department of Nephropathology

Involved external institutions

Boehringer Ingelheim Pharma GmbH & Co. KG DE Germany (DE)

How to cite

APA:

Luippold, G., Mark, M., Klein, T., Amann, K.U., & Daniel, C. (2018). Differences in kidney-specific DPP-4 inhibition by linagliptin and sitagliptin. Diabetes Research and Clinical Practice, 143, 199-203. https://dx.doi.org/10.1016/j.diabres.2018.07.009

MLA:

Luippold, Gerd, et al. "Differences in kidney-specific DPP-4 inhibition by linagliptin and sitagliptin." Diabetes Research and Clinical Practice 143 (2018): 199-203.

BibTeX: Download